Criteria and guidelines for combined therapy of type 2 diabetes. 2004 Consensus document;Criterios de control y pautas de tratamiento combinado en la diabetes tipo 2. Actualización 2004

Medicina Clinica

Volumn 123, Issue 5, 2004, Pages 187-197

  Goday Arno, Alberto ^a   Franch Nadal, Josep ^b   Mata Cases, Manuel ^c  

^a HOSPITAL DEL MAR   (Spain)

^b INSTITUT CATALÀ DE LA SALUT   (Spain)

^c CAP La Mina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BUFORMIN; CHLORPROPAMIDE; DIANBEN 850; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPENTIDE; GLIPIZIDE; GLIQUIDONE; GLUCOLON; GLUMINIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; NORGLICEM; PIOGLITAZONE; PLUMAROL; REPAGLINIDE; RONAME; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNI DIAMICRON;

ABDOMINAL PAIN; ARTICLE; CONSENSUS; DIARRHEA; EDEMA; FLATULENCE; HEART FAILURE; HUMAN; LACTIC ACIDOSIS; LIVER TOXICITY; MEDICAL DECISION MAKING; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE;

EID: 4043093433     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064241     Document Type: Article

References (66)

1. Goday A. Epidemiología de la diabetes mellitus y sus complicaciones no coronarias. Rev Esp Cardiol 2002;55:657-70.
2. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-52.
3. United Kingdom Prospective Diabetes Study Group. Effect of Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-64.
4. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. Multi-factorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
5. European Diabetes Policy Group 1998-1999, a desktop guide to type 2 diabetes mellitus. Diabetic Medicine 1999;16:716-30.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Clinical practice recomendations. Diabetes Care 2003;26(suppl 1):33-50.
7. Grupo de Estudio de la Diabetes en Atención Primaria de Salud (GE-DAPS). Guía para el tratamiento de la diabetes tipo 2 en la atención primaria. 3.a ed. Madrid: Harcourt, 2000.
8. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, et al. Clinical guidelines and evidence review for type 2 diabetes: Management of blood glucose. Sheffield: ScHARR, University of Sheffield. Disponible en: http://www.shef.ac.uk/guidelines/
9. DeFronzo RA. Pharmacologic therapy for type 2 Diabetes Mellitus. Ann Intern Med 1999;131:281-303.
10. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002;287:360-72.
11. Costa B. Nuevos enfoques terapéuticos en la diabetes tipo 2. Med Clin (Barc) 2001;117:137-41.
12. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
13. DeFronzo R, Goodman A. Efficacy of metformin in patients with NIDDM. N Engl J Med 1995;333:541-9.
14. Hermann LS, Schersten B, Bitzen PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994;17:1100-9.
15. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-34.
16. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-604.
17. Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A, Tisell A, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000;43:558-60.
18. Johnson JA, Simpson SH, Majumdar SR, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8.
19. Holman RR, Turner RC, Cull CA on behalf of the UKPDS Study Group. A randomized double-blind trial of Acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999;22:960-4.
20. Chiasson JL, Joss RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled trial. Ann Intern Med 1994;121:928-35.
21. Coniff R, Shapiro JA, Seaton T, Bray G. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plus- acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98:443-51.
22. Bayraktar M, Adalar N, Van Thiel DH. A comparison of acarbose versus metformin as an adjunt therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996;19:252-9.
23. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999;16:755-61 [erratum in: Diabet Med 2000;17:332].
24. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999;16:755-61 [erratum in: Diabet Med 2000;17:332].
25. Johnston PS, Santiago JV, Coniff RF, Hoogwerf, Pi-Sunyer FX, Krol A. Effects of the carbohidrate inhibitor miglitol in the sulfonylurea-treated non-insulin-dependent diabetes mellitus patients. Diabetes Care 1994;17:20-9.
26. Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2050-5.
27. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003;26:269-73.
28. Chiasson JL, Naditch L and the Miglitol Canadian Investigators Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 Diabetes. Diabetes Care 2001;24:989-4.
29. Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab 2001;3:326-31.
30. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24.
31. Horton ES, Clinkingbeard C, Gatlin M, Floey J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 Diabetes. Diabetes Care 2000;23:1660-5.
32. Marre M, Van Gaal L, Usadel KM, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002;4:177-86.
33. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, et al. Repaglinide vs nateglinide metformin combination study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26:2063-8.
34. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes. JAMA 2000;283:1695-702.
35. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409.
36. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan N. Addition of low-dose rosiglitazone to sulphonilurea improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7.
37. Kipnes MS, Krosnick A, Rendeli MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hidrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes. Am J Med 2001;111:10-7.
38. Raskin P, Jovanovic L, Berger S, Schwartz S, Wooo V, Ratner R. Repaglinide/troglitazone combination therapy. Improved glycemic control in type 2 diabetes. Diabetes Care 2000;23:979-83.
39. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003;26:1685-90.
40. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P; INS-206 study team. Insulin 70/30 mix plus metformin versus triple oral therapy in treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43.
41. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL for the Troglitazone-therapy Study. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulphonylurea and metformin: a multicenter, randomized, double-blind, placebo controlled trial. Ann Intern Med 2001;134:737-45.
42. Standl E, Schernthaner G, Rybka J, Hanefeld M, Raptios SA, Naditch L. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diab Res Clin Pract 2001;52:205-13.
43. Kiayias JA, Vlachou ED, Theodosopoulou EBN, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002;25:1251-2.
44. Peters AL, Davidson MB. Insulin plus sulphonylurea agent for treating type 2 diabetes. Ann Intern Med 1991;115:45-53.
45. Johnson JL, Wlf SL, Kabadi UM. Efficacy of Insulin and sulphonylurea combination therapy in type 2 diabetes. A meta-analysis of the Randomized placebo-controlled trials. Arch Intern Med 1996;156:259-64.
46. Yki-Jarvinen H, Kauppila M, Kjansuu E, Lahti J, Marjanen T, Ninskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
47. Yki-Jarvinen H, Ryysy L, Kauppila M, Kjansuu E, Lahti J, Marjanen T, et al. Effect of obesity on the response to insulin therapy in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:4037-43.
48. Costa B, Estopa A, Borras J, Sabaté A. Consumo de medicación en la diabetes mellitus (VI): economía y efectividad de la terapia combinada con insulina y sulfonilureas sobre la administració n convencional con dos dosis. Med Clin (Barc) 1998;11:568-72.
49. Riddle MC, Schneider J. Begining insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998;21:1052-7.
50. Wright A, Burden F, Paisey R, Cull C, Holman R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
51. Yki-Jarvinen H, Ryysy L, Nikkila K, Tolukas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-6.
52. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 1999;42:406-12.
53. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182-8.
54. Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus. An open-label randomized trial. Diabetic Med 1998;15:997-1002.
55. Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002;25:1685-90.
56. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25:2133-40.
57. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2056-61.
58. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995;18:928-32.
59. Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabet Med 1998;15:657-60.
60. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.
61. Rosenstock J, Einhorn D, Hershon K, Glazer NB. Efficacy and safety of ploglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7.
62. Strowig SM, Avilés-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691-8.
63. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6.
64. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003;138:952-9.
65. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96.
66. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003;20:545-51.